O	0	7	Primary
B-intervention	8	19	granulocyte
I-intervention	20	26	colony
I-intervention	26	27	-
I-intervention	27	38	stimulating
I-intervention	39	45	factor
I-intervention	46	57	prophylaxis
O	58	64	during
O	65	68	the
O	69	74	first
O	75	78	two
O	79	85	cycles
O	86	90	only
O	91	93	or
O	94	104	throughout
O	105	108	all
O	109	121	chemotherapy
O	122	128	cycles
O	129	131	in
O	132	140	patients
O	141	145	with
O	146	152	breast
O	153	159	cancer
O	160	162	at
O	163	167	risk
O	168	171	for
B-condition	172	179	febrile
I-condition	180	191	neutropenia
O	191	192	.

O	193	198	Early
O	199	205	breast
O	206	212	cancer
O	213	215	is
O	216	224	commonly
O	225	232	treated
O	233	237	with
O	238	252	anthracyclines
O	253	256	and
O	257	264	taxanes
O	264	265	.

O	266	273	However
O	273	274	,
O	275	284	combining
O	285	290	these
O	291	296	drugs
O	297	306	increases
O	307	310	the
O	311	315	risk
O	316	318	of
O	319	332	myelotoxicity
O	333	336	and
O	337	340	may
O	341	348	require
O	349	360	granulocyte
O	361	367	colony
O	367	368	-
O	368	379	stimulating
O	380	386	factor
O	387	388	(
O	388	389	G
O	389	390	-
O	390	393	CSF
O	393	394	)
O	395	402	support
O	402	403	.

O	404	407	The
O	408	415	highest
O	416	425	incidence
O	426	428	of
O	429	436	febrile
O	437	448	neutropenia
O	449	450	(
O	450	452	FN
O	452	453	)
O	454	457	and
O	458	465	largest
O	466	473	benefit
O	474	476	of
O	477	478	G
O	478	479	-
O	479	482	CSF
O	483	489	during
O	490	493	the
O	494	499	first
O	500	506	cycles
O	507	509	of
O	510	522	chemotherapy
O	523	527	lead
O	528	530	to
O	531	540	questions
O	541	546	about
O	547	550	the
O	551	564	effectiveness
O	565	567	of
O	568	577	continued
O	578	581	use
O	582	584	of
O	585	586	G
O	586	587	-
O	587	590	CSF
O	591	601	throughout
O	602	607	later
O	608	614	cycles
O	615	617	of
O	618	630	chemotherapy
O	630	631	.

O	632	634	In
O	635	636	a
O	637	648	multicenter
O	649	654	study
O	654	655	,
B-eligibility	656	664	patients
I-eligibility	665	669	with
I-eligibility	670	676	breast
I-eligibility	677	683	cancer
I-eligibility	684	687	who
I-eligibility	688	692	were
I-eligibility	693	703	considered
I-eligibility	704	707	fit
I-eligibility	708	714	enough
I-eligibility	715	717	to
I-eligibility	718	725	receive
I-eligibility	726	727	3
I-eligibility	727	728	-
I-eligibility	728	734	weekly
I-eligibility	735	751	polychemotherapy
I-eligibility	751	752	,
I-eligibility	753	756	but
I-eligibility	757	761	also
I-eligibility	762	765	had
I-eligibility	766	767	>
I-eligibility	768	770	20
I-eligibility	770	771	%
I-eligibility	772	776	risk
I-eligibility	777	780	for
I-eligibility	781	783	FN
O	783	784	,
O	785	789	were
O	790	798	randomly
O	799	807	assigned
O	808	810	to
O	811	818	primary
O	819	820	G
O	820	821	-
O	821	824	CSF
O	825	836	prophylaxis
O	837	843	during
O	844	847	the
O	848	853	first
O	854	857	two
O	858	870	chemotherapy
O	871	877	cycles
O	878	882	only
O	883	884	(
O	884	896	experimental
O	897	900	arm
O	900	901	)
O	902	904	or
O	905	907	to
O	908	915	primary
O	916	917	G
O	917	918	-
O	918	921	CSF
O	922	933	prophylaxis
O	934	944	throughout
O	945	948	all
O	949	961	chemotherapy
O	962	968	cycles
O	969	970	(
B-control	970	978	standard
I-control	979	982	arm
O	982	983	)
O	983	984	.

O	985	988	The
O	989	1003	noninferiority
O	1004	1014	hypothesis
O	1015	1018	was
O	1019	1023	that
O	1024	1027	the
O	1028	1037	incidence
O	1038	1040	of
O	1041	1043	FN
O	1044	1049	would
O	1050	1052	be
O	1053	1062	maximally
O	1063	1064	7
O	1064	1065	.
O	1065	1066	5
O	1066	1067	%
O	1068	1074	higher
O	1075	1077	in
O	1078	1081	the
O	1082	1094	experimental
O	1095	1103	compared
O	1104	1108	with
O	1109	1112	the
O	1113	1121	standard
O	1122	1125	arm
O	1125	1126	.

O	1127	1132	After
O	1133	1142	inclusion
O	1143	1145	of
B-total-participants	1146	1149	167
O	1150	1158	eligible
O	1159	1167	patients
O	1167	1168	,
O	1169	1172	the
O	1173	1184	independent
O	1185	1189	data
O	1190	1200	monitoring
O	1201	1210	committee
O	1211	1218	advised
O	1219	1228	premature
O	1229	1234	study
O	1235	1242	closure
O	1242	1243	.

O	1244	1246	Of
B-control-participants	1247	1249	84
O	1250	1258	patients
O	1259	1267	randomly
O	1268	1276	assigned
O	1277	1279	to
O	1280	1281	G
O	1281	1282	-
O	1282	1285	CSF
O	1286	1296	throughout
O	1297	1300	all
O	1301	1313	chemotherapy
O	1314	1320	cycles
O	1320	1321	,
B-cv-bin-abs	1322	1327	eight
O	1328	1329	(
B-cv-bin-percent	1329	1331	10
I-cv-bin-percent	1331	1332	%
O	1332	1333	)
O	1334	1345	experienced
O	1346	1348	an
B-outcome	1349	1356	episode
I-outcome	1357	1359	of
I-outcome	1360	1362	FN
O	1362	1363	.

O	1364	1366	In
O	1367	1375	contrast
O	1375	1376	,
O	1377	1379	of
B-intervention-participants	1380	1382	83
O	1383	1391	patients
O	1392	1400	randomly
O	1401	1409	assigned
O	1410	1412	to
O	1413	1414	G
O	1414	1415	-
O	1415	1418	CSF
O	1419	1425	during
O	1426	1429	the
O	1430	1435	first
O	1436	1439	two
O	1440	1446	cycles
O	1447	1451	only
O	1451	1452	,
B-iv-bin-abs	1453	1455	30
O	1456	1457	(
B-iv-bin-percent	1457	1459	36
I-iv-bin-percent	1459	1460	%
O	1460	1461	)
O	1462	1465	had
O	1466	1468	an
B-outcome	1469	1471	FN
I-outcome	1472	1479	episode
O	1480	1481	(
O	1481	1483	95
O	1483	1484	%
O	1485	1487	CI
O	1487	1488	,
O	1489	1490	0
O	1490	1491	.
O	1491	1493	13
O	1494	1496	to
O	1497	1498	0
O	1498	1499	.
O	1499	1501	54
O	1501	1502	)
O	1502	1503	,
O	1504	1508	with
O	1509	1510	a
O	1511	1515	peak
O	1516	1525	incidence
O	1526	1528	of
O	1529	1531	24
O	1531	1532	%
O	1533	1535	in
O	1536	1539	the
O	1540	1545	third
O	1546	1551	cycle
O	1552	1553	(
O	1553	1555	ie
O	1555	1556	,
O	1557	1562	first
O	1563	1568	cycle
O	1569	1576	without
O	1577	1578	G
O	1578	1579	-
O	1579	1582	CSF
O	1583	1594	prophylaxis
O	1594	1595	)
O	1595	1596	.

O	1597	1599	In
O	1600	1608	patients
O	1609	1613	with
O	1614	1619	early
O	1620	1626	breast
O	1627	1633	cancer
O	1634	1636	at
O	1637	1641	high
O	1642	1646	risk
O	1647	1650	for
O	1651	1653	FN
O	1653	1654	,
O	1655	1664	continued
O	1665	1668	use
O	1669	1671	of
O	1672	1679	primary
O	1680	1681	G
O	1681	1682	-
O	1682	1685	CSF
O	1686	1697	prophylaxis
O	1698	1704	during
O	1705	1708	all
O	1709	1721	chemotherapy
O	1722	1728	cycles
O	1729	1731	is
O	1732	1734	of
O	1735	1743	clinical
O	1744	1753	relevance
O	1754	1757	and
O	1758	1762	thus
O	1763	1769	cannot
O	1770	1772	be
O	1773	1782	abandoned
O	1782	1783	.
